Rabbit Polyclonal Antibody
Catalog No. J02-63R
|Catalog No.||Pack Size||Price (USD)|
JAK2 is a member of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway (1). JAK2 has two near-identical phosphate-transferring domains. One domain exhibits the kinase activity while the other stabilizes the JAK conformational structure. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon (2).
1. Lacronique, V. Et al : A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 1997; 278: 1309-1312.
2. Ho, J.M. et al: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood, 2002; 100: 1438-1448.
Recognizes the JAK2 protein
Western blot JAK2 from human and mouse cells
JAK2 from other species may also be detectable.
Synthetic peptide corresponding to amino acids 1005-1009 of human JAK2
Store at 4°C (add 0.1% NaN3) for several months, and at -20°C for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Representative western blot with Anti-JAK2 (1:1000) using 20 ng of human recombinant JAK1 and JAK2.
Representative western blot with Anti-JAK2 (1:1000) using 30 μg of HeLa, HEK-293T, Jurkat, THP1, and 3T6 cell lysate.
Scuto A et al., The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival Leukemia March 2011 10.1038/leu.2010.289
Huang Yongqi et al., The Activity and Stability of the Intrinsically Disordered Cip/Kip Protein Family AreRegulated by Non-Receptor Tyrosine Kinases Journal of Molecular Biology January 2015 10.1016/j.jmb.2014.11.011
Zhang Jing et al., Dehydrocrenatidine is a Novel JAK Inhibitor Molecular Pharmacology January 2015 10.1124/mol.114.095208
Deng Yang et al., Global Analysis of Human Nonreceptor Tyrosine Kinase Specificity Using High-Density Peptide Microarrays Journal of Proteome Research August 2014 10.1021/pr500503q
JW Singer et al., Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of Experimental Pharmacology August 2016 10.2147/JEP.S110702
Kesarwani Meenu et al., Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance Science Reports September 2015 10.1038/srep14538
Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway